Drugs and patents in ATC class M01AX - Other antiinflammatory and antirheumatic agents, non-steroids

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
NABUMETONE	nabumetone
RELAFEN	nabumetone
>Tradename	>Generic Name

Last updated: July 28, 2026

Executive summary: ATC M01AX is a heterogeneous, “other” bucket that includes small-molecule and specialty non-steroidal anti-inflammatory and anti-rheumatic agents not fitting into more specific ATC subclasses. The patent landscape is therefore fragmented by active ingredient, with exclusivity driven primarily by (1) composition-of-matter and (2) specific use (method-of-treatment) and (3) formulation or delivery improvements for select entrants. Near-term generic or biosimilar risk concentrates where originator assets have aged into the 2020s, where FDA approvals sit on established reference products, and where Paragraph IV litigation has already been filed for specific actives. Growth opportunities concentrate where differentiation is tied to dosing, safety, and route of administration rather than broad chemical novelty.

Which drugs sit inside ATC M01AX and what market share risks follow from “other” categorization?

Featured snippet answer: M01AX is an ATC “residual” class. Market dynamics are driven by the specific active ingredient mix inside the bucket, not by the subclass label itself. Patent and generic risk map 1:1 to each active ingredient’s Orange Book listing, biologic status (if any), and litigation history.

How M01AX breaks down by active ingredients

ATC M01AX typically captures non-steroidal anti-inflammatory and anti-rheumatic agents that do not fit established subclasses such as COX-2 selective agents, salicylates, propionic acid derivatives, acetic acid derivatives, etc. Practically, the competitive set for M01AX is best treated as a portfolio of actives.

What “other” class membership changes for IP strategy

Because the class aggregates disparate chemotypes and delivery formats, each active ingredient’s patent estate needs to be evaluated on its own:

Small-molecule generics: IP risk is usually driven by composition-of-matter expiration, then “evergreen” formulation or dosing patents, then method-of-use claims.
Specialty/nontraditional products: risk can be driven by device delivery, prodrug switching, or extended-release formulation claims that are harder to design around.
Safety-driven differentiation: if differentiation depends on dosing regimen claims, Paragraph IV challenges can be constrained by method-of-use coverage.

How strong is the patent estate for M01AX drugs and what claim types dominate?

Featured snippet answer: Across M01AX actives, patents most commonly cluster around composition-of-matter, specific crystalline forms or polymorphs, formulation blends, and method-of-use (including dosing and patient subgroups). The strongest estates usually combine early foundational chemistry with later filings on formulation and clinical regimen.

Claim-type map used to triage M01AX IP

For business and litigation planning, M01AX estates usually break into:

Composition-of-matter: original active ingredient or salts, solvates, polymorphs.
Formulation: extended-release matrices, taste-masking, permeability enhancers, prodrug conversion, combination tablets.
Method-of-use: specific dosing schedules, lines of therapy, disease stage, refractory patient selection.
Manufacturing process: specific granulation, drying, or solvent-removal steps that can create hard-to-evade procedural infringement.

Where patent estates tend to be weakest

If the originator’s later patents are limited to narrow formulation parameters, generics can design around by changing excipient set, coating thickness, or release profile while staying within bioequivalence.
If method-of-use coverage is absent or not supported by robust clinical examples, infringement arguments weaken.

When does exclusivity end for M01AX non-steroidal anti-inflammatory and antirheumatic agents?

Featured snippet answer: Exclusivity timelines differ per active ingredient. In practice, generic entry risk accelerates after composition-of-matter expiry, then extends where formulation or method-of-use patents remain in force.

Exclusivity structure that typically applies

For each active ingredient inside M01AX, exclusivity timing usually tracks:

New chemical entity or new formulation exclusivities (for the drug product, not for the molecule).
Regulatory exclusivity under the US Hatch-Waxman framework where applicable.
Patent term expiration (PTT) for composition-of-matter.
Remaining ancillary patents (formulations, use, manufacturing).

Generic launch risk staging

Stage 1: launch after patent expiry with no relevant blocking patents in Orange Book.
Stage 2: launch blocked by one or more formulation or method-of-use patents; Para-IV filings can trigger settlements that delay launch.
Stage 3: “authorized generic” or delayed-launch strategies may follow settlement.

What Orange Book status exists for M01AX drugs and how does it shape generic entry?

Featured snippet answer: Orange Book status determines whether FDA-cleared generics can cite to a reference listed drug and whether Paragraph IV challenges can be brought. For M01AX, the Orange Book’s “listed patents” set the effective launch timetable by blocking device (BMS) patents.

Orange Book status drivers

Listed drug (RLD) and dosage form: tablets vs capsules vs ER forms often carry different listed patent sets.
Patents listed: each formulation or method-of-use patent listed creates an entry barrier unless carved out by FDA labeling carveouts or design-around work.
Expiry mapping: the earliest-to-expire “blocking” patent often defines launch date more than the broader claim portfolio.

Litigation effect on Orange Book

If Paragraph IV litigation results in a court decision or settlement, the effective launch date can shift materially away from the earliest patent expiry.

Which M01AX drugs face Paragraph IV challenges and settlement delays?

Featured snippet answer: Paragraph IV challenges concentrate around mature originator actives where Orange Book patents remain listed near the end of patent terms. Settlement delays are the usual mechanism when uncertainty on claim scope and infringement is high.

How to evaluate Paragraph IV risk for each active ingredient

A standardized approach:

Identify RLD(s) and the listed patents.
Classify patents into composition vs formulation vs method-of-use.
Check the history of Paragraph IV filings, court outcomes, and settlement agreements for each listed patent.
Model carveout labeling changes and whether method-of-use claims are likely to be triggered.

What settlement structures typically do in M01AX

Launch-forcing settlements: generic agrees to delayed entry and sometimes dismisses or narrows challenges.
Narrow carveouts: originator may accept a labeling carveout that avoids method-of-use claims.
Authorized generics: originator or authorized partner may block competition with a controlled channel.

How do formulations and delivery patents affect design-around for M01AX generics?

Featured snippet answer: Formulation and delivery patents are often the practical gatekeepers even when composition-of-matter has aged. For M01AX, the hardest design-around tends to involve extended release, solubility control, and specific manufacturing steps.

Formulation patent levers commonly asserted

Extended-release matrices: drug release profile targets can be claim-critical.
Polymorph/crystal engineering: claims tied to specific forms can force generic to prove non-infringement analytically.
Co-crystals and solvates: can increase manufacturing complexity and compliance testing.
Combination products: if a fixed-dose combo sits in M01AX, combination patents can block entry even when each component is individually off-patent.

Manufacturing patents as litigation multipliers

If manufacturing-step patents are asserted, infringement can turn on process replication in the generic facility, raising:

discovery cost,
proof of infringement burdens,
potential for injunction leverage.

What method-of-use patents for M01AX block labeling carveouts?

Featured snippet answer: Method-of-use patents can block generic entry when the FDA labeling cannot be carved out cleanly. If claims tie to broad disease indications without clean labeling boundaries, generics face higher launch friction.

Common method-of-use coverage patterns

Dosing regimen (frequency, titration, duration).
Patient subpopulation (refractory status, prior therapy).
Disease stage (moderate to severe, flare management).
Combination treatment sequences.

Labeling carveout feasibility

Clean carveouts become possible when the originator labeling is narrow and the generic can omit the exact claimed regimen.
Carveouts fail when the generic must market the product for the same indication and regimen to remain commercially viable.

Which companies are competing in ATC M01AX and where does patent risk concentrate?

Featured snippet answer: Competition is active among originator pharmaceutical companies and multiple generic manufacturers, with the highest patent risk concentrated in long-tail formulation and method-of-use assets for specific actives.

Competitor mapping approach

For each M01AX active ingredient, map:

Originator assignee holding the patents.
Generics filing early Paragraph IV to each listed patent family.
Settlement parties and authorized generic holders.

Risk concentration logic

Patent risk is highest when:

there are multiple listed patents with staggered expiries,
multiple dosage strengths are covered,
court injunction risk is credible based on claim strength and infringement evidence.

How do M01AX patent estates compare versus other non-steroidal anti-inflammatory buckets (e.g., M01AB/ M01AE)?

Featured snippet answer: Compared with more chemically homogeneous subclasses, M01AX estates are more fragmented. Patent strategies more often rely on formulation and use-specific claims than on broad chemical exclusivity spanning a large single molecule universe.

Business implication

A generic strategy in M01AX usually needs:

active ingredient-by-active ingredient litigation diligence,
strong formulation non-infringement plans,
readiness to negotiate labeling carveouts or accept launch delay.

What does the FDA regulatory pathway imply for generics in M01AX?

Featured snippet answer: For M01AX small-molecule drugs with listed Orange Book patents, FDA pathway timing is shaped by whether generics can file ANDA with Paragraph IV certifications to listed patents and whether litigation or settlements delay approval.

Typical generic pathway constraints

ANDAs referencing the RLD with listed patents.
Paragraph IV certification triggers litigation timelines and potential automatic 30-month stay.
Court outcomes and settlements determine the effective approval and launch window.

Biosimilar risk exists in M01AX?

Featured snippet answer: True biosimilar risk is typically not the main driver for M01AX, which is mainly populated by small molecules. Risk is more often from generics and authorized generics rather than biosimilars.

When biologic-like risks could appear

Only where a product’s classification is atypical for M01AX or where future entrants include biologics mistakenly captured by ATC mapping. In standard M01AX planning, generics dominate.

Revenue exposure: which M01AX segments have the most cash-flow at stake from patent expiry?

Featured snippet answer: Cash-flow exposure concentrates in the actives with the highest US prescription volume and the longest tail of listed patents by dosage strength and formulation.

How to quantify exposure in practice

Use a per-RLD basis:

originator US sales,
peak market share,
number of listed patents and staggered expiries,
presence of Paragraph IV challenges and settlement delays.

Generic entry scenarios for M01AX: launch timing playbook

Featured snippet answer: For each active ingredient, there are three practical scenarios: (1) straightforward expiry launch, (2) delayed launch via settlement, (3) partial launch with labeling carveouts.

Scenario model

Expiry-first scenario: earliest blocking patent expires; ANDA approval and launch proceed without settlement.
Settlement-delay scenario: settlement grants delayed launch; generic enters later, sometimes with restricted labeling.
Design-around scenario: generic remains outside claim scope through formulation or process changes and launches on a faster timetable.

Key takeaways

ATC M01AX is not a single patent story. The subclass is a residual bucket; patent and generic risk is determined by each active ingredient’s Orange Book listed patents and litigation history.
The highest-friction assets for M01AX generics are typically formulation/delivery patents and method-of-use patents that resist clean labeling carveouts.
Exclusivity and generic launch timing should be modeled at the RLD and patent-family level, not at the ATC subclass level.
Market entry for generics usually hinges on (1) whether composition-of-matter has expired and (2) whether any later-listed blocking patents remain enforceable and are covered by active litigation or settlements.

FAQs

Which ATC M01AX actives have the most Orange Book listed patents and the longest tail of blocking coverage?
How do Paragraph IV settlements typically change ANDA launch dates for M01AX drugs?
What types of formulation claims in M01AX most often survive design-around attempts?
Can generics avoid method-of-use infringement in M01AX through labeling carveouts, and when do carveouts fail?
How should M01AX patent due diligence be prioritized for investors versus generic entrants?

References

American Hospital Formulary Service. Drug information resources and ATC classification context.
FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
FDA. Hatch-Waxman ANDA and Paragraph IV certification framework.
FDA. Drug Development and Approval Process (ANDAs, exclusivity concepts).